Alnylam Pharmaceuticals
ALNY
498 hedge funds and large institutions have $17.2B invested in Alnylam Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 204 increasing their positions, 151 reducing their positions, and 64 closing their positions.
51% more call options, than puts
Call options by funds: $461M | Put options by funds: $304M
35% more repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 151
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
13% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 64
0% more funds holding
Funds holding: 498 → 498 (0)
2.79% less ownership
Funds ownership: 93.94% → 91.15% (-2.8%)
24% less capital invested
Capital invested by funds: $22.6B → $17.2B (-$5.4B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$160M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$139M |
| 3 |
BlackRock
New York
|
+$84.1M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$52.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$565M |
| 2 |
RI
RTW Investments
New York
|
-$314M |
| 3 |
JP Morgan Chase
New York
|
-$212M |
| 4 |
Morgan Stanley
New York
|
-$156M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$135M |
ALNY Hedge Fund Activity: Q1 2024 in Review
498 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2024, worth a combined $17.2B — down 24% from $22.6B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new ALNY positions and 64 closed out — a net gain of 8 holders — while 204 added to existing stakes and 151 trimmed.
The largest buyer was American Century Companies, adding an estimated $160M. The largest seller was Capital World Investors, cutting an estimated $565M.
- 498 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $17.2B of Alnylam Pharmaceuticals stock for Q1 2024, down 24% quarter-over-quarter.
- 72 funds opened new Alnylam Pharmaceuticals positions in Q1 2024 and 64 closed out, a net change of +8 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2024 was American Century Companies, an estimated $160M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2024 was Capital World Investors, an estimated $565M sold.
Based on aggregated 13F filings for Q1 2024.